Möchten Sie immer auf dem neuesten Stand bleiben?

Media ReleaseCopenhagen, Denmark, March 11, 2019 Genmab A/S (Nasdaq Copenhagen: GEN) announced today that Marisol Peron has been appointed Corporate Vice President, Communications and Investor...

Company Announcement Copenhagen, Denmark; March 1, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting the board decided to grant 6,397 restricted stock units and...

Company Announcement Genmab A/S to hold Annual General Meeting on March 29, 2019 Copenhagen, Denmark; Thursday, February 28, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) summons the Annual General...

Company Announcement Copenhagen, Denmark; February 26, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 26,297 shares as a consequence of the exercise of employee...

Company Announcement Phase III COLUMBA study comparing the subcutaneous formulation of daratumumab to the intravenous formulation in patients with relapsed or refractory multiple myeloma met both...

Company Announcement Copenhagen, Denmark; February 20, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today its Annual Report for 2018.  Below is a summary of business progress and...

Media Release Copenhagen, Denmark, February 12, 2019 DARZALEX split dosing regimen approved by U.S. FDAProvides healthcare professionals with option to split first DARZALEX infusion over two...

Company Announcement Genmab, Janssen and MorphoSys have agreed to end the patent infringement lawsuit launched by MorphoSys AG relating to DARZALEXOn January 25, 2019, a summary judgement decision...

Company Announcement Patents asserted against Janssen Biotech, Inc. & Genmab in the United States have been declared invalid by summary judgment Copenhagen, Denmark; January 26, 2019 – Genmab...

Company Announcement First part of regulatory package submitted to the U.S. FDA for label expansion of daratumumab in combination with lenalidomide and dexamethasone for patients with newly...